Volume 2, Issue 4 (Journal of Clinical and Basic Research(JCBR) 2018)                   jcbr 2018, 2(4): 8-14 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shokri Z, Atabaki Pasdar F, Ayatollahi H, Naji S, Farjah G H. Predictive Value of Helix Pomatia Agglutinin (HPA) Lectin in Management of Complete Hydatidiform Mole. jcbr. 2018; 2 (4) :8-14
URL: http://jcbr.goums.ac.ir/article-1-166-en.html
1- Department of Anatomical Sciences, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2- Department of Gynecology & Obstetrics , Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran
3- Department of Pathology, Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran
4- Neurophysiology Research Center, Department of Anatomical Sciences, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract:   (1137 Views)
Background and objectives: Hydatidiform mole is the most common form of gestational trophoblastic disease, which originates from the placenta and is categorized into complete and partial hydatidiform moles. About 10-30% of complete hydatidiform moles (CHMs) might develop into persistent trophoblastic disease. Helix pomatia agglutinin (HPA) lectin has been suggested as a marker of alteration of glycosylation in human malignancies. The aim of this study was to determine efficacy of HPA lectin as a prognostic indicator for clinical behavior of CHMs.
Methods: Lectin histochemistry with biotin-conjugated HPA lectin was performed on paraffin sections of CHM tissues from 24 patients with progression to persistent trophoblastic disease (case group) and 24 patients with spontaneous regression (control group). The sections were graded according to lectin staining intensity (0-3) and the percentage of cell reactions was evaluated based on the staining grades.
Results: HPA lectin showed a mild to moderate reactivity with syncytiotrophoblasts, which was most evident in apical portion, but did not react with cytotrophoblasts and stromal cells. The mean staining intensity values did not differ significantly between the two groups (P=0.447).
Conclusion: Based on the results, HPA lectin is not a good prognostic indicator for clinical behavior of CHMs.
Full-Text [PDF 469 kb]   (277 Downloads)    
Article Type: Research | Subject: Medicine
Received: 2018/12/27 | Accepted: 2018/12/27 | Published: 2018/12/27

1. Niemann I, Vejerslev L, Froding L, et al. Gestational Trophoblastic Diseases, Clinical guidelines for diagnosis, treatment, follow-up, and counseling. Danish Med J. 2015; 62(11): 1-19.
2. Alhamdan D, Bignardi T, Condous G. Recognising gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2009; 23(4): 565-73. [DOI:10.1016/j.bpobgyn.2009.03.001]
3. LeGallo RD, Stelow EB, Ramirez NC, Atkins KA. Diagnosis of hydatidiform moles using p57 immunohistochemistry and HER2 fluorescent in situ hybridization. Am J Clin Pathol. 2008; 129(5): 749-55. [DOI:10.1309/7XRL378C22W7APBT]
4. Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol. 2013; 128(1): 3–5. [DOI:10.1016/j.ygyno.2012.07.116]
5. Ngan HYS, Kohorn EI, Cole LA, Kurman RJ, , Kim SJ, Lurain JR, et al. Trophoblastic disease. International Journal of Gynecology and Obstetrics. 2012; 119: 130-136. [DOI:10.1016/S0020-7292(12)60026-5]
6. Hegab HM, Schindler AE. The prognostic value of serum inhibin, 17 beta- estradiol and progestrone in cases of hydatidiform mole. Gynecol Endocrinol. 2004; 18(2): 107-13. [DOI:10.1080/09513590310001652991]
7. Kubelka-Sabit KB, Prodanova I, Jasar D, et al. Molecular and Immunohistochemical Characteristics of Complete Hydatidiform Moles. Balkan J Med Genet. 2017; 20(1): 27-34. [DOI:10.1515/bjmg-2017-0009]
8. Atabaki Pasdar F, Khooei A, Fazel A, Mahmoudi M, Nikravesh MR, Khaje Delui M. Diagnostic value of lectins in differentiation of molar placentas. Iran J Basic Med Sci. 2012; 15(6): 1140-7.
9. Samadder A, Kar R. Utility of p57 immunohistochemistry in differentiating between complete mole, partial mole & non-molar or hydropic abortus. Indian J Med Res. 2017; 145(1): 133–137. [DOI:10.4103/ijmr.IJMR_982_15]
10. Rambaruth ND1, Greenwell P, Dwek MV. The lectin Helix pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human breast cancer. Glycobiology. 2012; 22(6): 839-48. [DOI:10.1093/glycob/cws051]
11. Brooks SA, Leathem AJ, Camplejohn RS, Gregory W. Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy. Breast Cancer Res Treat. 1993; 25(3): 247-56. [DOI:10.1007/BF00689839]
12. Welinder C, Jansson B, Ferno M, Olson H, Baldetorp B. Expression of Helix Pomatia Lectin Binding Glycoproteins in women with breast cancer in relationship to their blood group. J Proteome Res. 2009; 8(2): 782-7. [DOI:10.1021/pr800444b]
13. Brooks SA. The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression. Histol Histopathol 2000; 15(1): 143–158.
14. Kakeji Y, Tsujitani S, Mori M, Maehara Y, Sugimachi K. Helix pomatia agglutinin binding activity is a predictor of survival time for patients with gastric carcinoma. Cancer 1991; 68: 2438–2442. https://doi.org/10.1002/1097-0142(19911201)68:11<2438::AID-CNCR2820681119>3.0.CO;2-# [DOI:10.1002/1097-0142(19911201)68:113.0.CO;2-#]
15. Arab MR, Salari S, Karimi M, Mofidpour H. Lectin histochemical study of cell surface glycoconjugate in gastric carcinoma using helix pomatia agglutinin. Acta Med Iran. 2010; 48(4): 209-13.
16. Saint-Guirons J, Zeqiraj E, Schumacher U, Greenwell P, Dwek M. Proteome analysis of metastatic colorectal cancer cells recognized by the lectin Helix pomatia agglutinin (HPA). Proteomics. 2007; 7(22): 4082-4089. [DOI:10.1002/pmic.200700434]
17. Schumacher U, Higgs D, Loizidou M, Pickering R, Leathem A, Taylor I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer. 1994; 74: 3104–3107. https://doi.org/10.1002/1097-0142(19941215)74:12<3104::AID-CNCR2820741207>3.0.CO;2-0 [DOI:10.1002/1097-0142(19941215)74:123.0.CO;2-0]
18. Shiraishi T, Atsumi S, Yatani R. Comparative study of prostatic carcinoma bone metastasis among Japanese in Japan and Japanese Americans and whites in Hawaii. Adv Exp Med Biol. 1992; 324: 7–16. [DOI:10.1007/978-1-4615-3398-6_2]
19. Thower S, Bulmer JN. Further studies of lectin binding by villous and extravillous trophoblast in normal and pathological pregnancy. Int J Gynecol Pathol. 1991; 10(3): 238-251. [DOI:10.1097/00004347-199107000-00003]
20. Arab M, Sepehri Z, Eimani H, Karimi M, Sargolzaie F. Histochemical Study of N-acetylgalactosamine Containing Glycoconjugate in Intraductal Carcinoma of the Breast by HPA Lectin. Yakhteh Med J. 2006; 7(4): 216-221.
21. Korourian S, Siegel E, Kieber-Emmons T, Monzavi-Karbassi B. Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry. BMC Cancer. 2008; 14; 8:136.
22. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Trophoblastic disease. International Journal of Gynecology and Obstetrics. 2015; 131: 123-126. [DOI:10.1016/j.ijgo.2015.06.008]
23. Horn LC, Kowalzik J, Bilek K, Richter CE, Einekel J. Prognostic value of trophoblastic proliferation in complete hydatidiform moles in predicting persistent diseases. Pathol Res & Pract. 2006 (202): 151 156. [DOI:10.1016/j.prp.2005.11.009]
24. Bae SN, Kim SJ. Telomerase activity in complete hydatidiform mole. Am J Obstet Gynecol. 1998; 180(2): 328-333. [DOI:10.1016/S0002-9378(99)70208-5]
25. Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol. 2001; 20(1): 31–47. [DOI:10.1097/00004347-200101000-00004]
26. Jones CJ, Dantzer V, Leiser R, Krebs C, Stoddart RW. Localisation of glycans in the placenta: a comparative study of epitheliochorial, endotheliochorial, and haemomonochorial placentation. Microsc Res Tech. 1997; 38(1-2): 100–14. https://doi.org/10.1002/(SICI)1097-0029(19970701/15)38:1/2<100::AID-JEMT11>3.0.CO;2-T [DOI:10.1002/(SICI)1097-0029(19970701/15)38:1/23.0.CO;2-T]
27. Whyte A. Lectin binding by microvillous membranes and coated-pit regions of human syncytial trophoblast. Histochem J. 1980; 12(5): 599–607. [DOI:10.1007/BF01011933]
28. Lee MC, Damjanov I. Lectin histochemistry of human placenta. Differentiation. 1984; 28(2): 123–8. [DOI:10.1111/j.1432-0436.1984.tb00275.x]
29. Brooks SA, Lymborus M,Schumacher U, Leathem AJ . Histochemistry to detect Helix Pomatia lectin in Breast Cancer: methodology makes a differences. J Histochem Cytochem. 1996; 44: 519-24. [DOI:10.1177/44.5.8627008]
30. Gusterson BA. Prognostic Value of Helix Pomatia in Breast Cancer. Br J Cancer 1993;68:146-50. [DOI:10.1038/bjc.1993.303]
31. Taylor CW, Anbazhagan R, Jayatilake H, et al. Helix Pomatia in Breast Cancer. Lancet. 1991; 338: 580-584. [DOI:10.1016/0140-6736(91)91154-M]
32. Schumacher DU, Randall CJ, Ramsay AD, Schumacher U. Is the binding of the lectin Helix pomatia agglutinin (HPA) of prognostic relevance in tumours of the upper aerodigestive tract? Eur J Surg Oncol. 1996; 22(6): 618-20. [DOI:10.1016/S0748-7983(96)92424-5]
33. Yoshida Y, Okamura T, Yano K, Taga S, Ezaki T. Histopathological characteristics associated with long-term survival in stage III esophageal carcinoma. Cancer. 1994; 7: 147-9.
34. Gauster M1, Blaschitz A, Siwetz M, Huppertz B. Keratins in the human trophoblast. Histol Histopathol. 2013; 28(7): 817-25.

Add your comments about this article : Your username or Email:

© 2020 All Rights Reserved | Journal of Clinical and Basic Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.